Literature DB >> 21314481

Short communication: severe immune suppression in patients infected with R5-tropic HIV-1 strains is associated with increased gp120 net charge at variable regions.

Eduardo Seclén1, Vincent Soriano, María del Mar González, Juan González-Lahoz, Eva Poveda.   

Abstract

CXCR4-tropic viruses have been associated with advanced immune suppression. However, 50% of patients with AIDS exclusively harbor CCR5-tropic viruses. The net charge at HIV-1 envelope gp120 variable regions was examined in 66 HIV-1-infected individuals with CCR5-tropic viruses, of whom 30 had less than 200 cells/mm(3). A positive net charge at gp120 variable regions was significantly associated with lower CD4 counts. Thus, the net charge at gp120 variable regions could influence HIV-1 disease progression in subjects with CCR5-tropic viruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314481     DOI: 10.1089/AID.2010.0359

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  3 in total

1.  Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications.

Authors:  Maria Paz Gonzalez-Perez; Paul J Peters; Olivia O'Connell; Nilsa Silva; Carole Harbison; Sheila Cummings Macri; Saravanan Kaliyaperumal; Katherine Luzuriaga; Paul R Clapham
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

2.  Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue.

Authors:  Maria Paz Gonzalez-Perez; Olivia O'Connell; Rongheng Lin; W Matthew Sullivan; Jeanne Bell; Peter Simmonds; Paul R Clapham
Journal:  Retrovirology       Date:  2012-03-15       Impact factor: 4.602

3.  Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression.

Authors:  For Yue Tso; Levon Abrahamyan; Shiu-Lok Hu; Ruth M Ruprecht; Charles Wood
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.